. Author manuscript; available in PMC: 2018 Jun 1.

Published in final edited form as: Curr Opin Virol. 2017 May 10;24:70–78. doi: 10.1016/j.coviro.2017.03.015

Table 2. Recently completed and current RSV vaccine clinical trials.

A wide array of clinical trials – from Phase I to Phase III, with a variety of vaccine strategies - are currently underway or were recently completed.

Vaccine Type	Mechanism of Action	Clinical Trials
Live-attenuated	M2-2 gene deletion	LID ΔM2-2 1030s Phase I: NCT02794870, NCT02952339 LID cp ΔM2-2 Phase I: NCT02948127, NCT02890381
	SH gene deletion	MEDI–599 Phase I/IIa: NCT00767416 RSV cps2 Phase I: NCT01852266, NCT01968083
	NS2 gene deletion	RSV ΔNS2 A1313 I1314L Phase I: NCT01893554
	PIV3 vector^*	MEDI–534 Phase I: NCT00345670, NCT00493285 Phase I/IIa: NCT00686075
Vector delivery system	Adenovirus vector	GSK3389245A Phase I: NCT02491463 Phase II: NCT02927873 GSK3003891A Phase I: NCT01905215 Phase II: NCT02360475, NCT02956837, NCT02753413, VXA-RSV-f Phase I: NCT02830932 Ad26.RSV.FA2 and Ad35.RSV.FA2 Phase I: NCT02440035, NCT02561871
Vector delivery system	Modified Vaccinia Ankara vector	PanAd3-RSV and MVA-RSV Phase I: NCT01805921 MVA-BN Phase I: NCT02419391
Protein-based	F-protein nanoparticle, with an aluminum hydroxide adjuvant	Nanoparticle vaccine Phase I: NCT02296463, NCT01290419, NCT01709019, Phase II: NCT02247726, NCT01704365, NCT01960686, NCT02593071, NCT02266628, Phase III: NCT02608502, NCT02624947
Protein-based	Post-fusion F glycoprotein, with glucopyranosyl lipid A adjuvant	MEDI-7510 Phase I: NCT02115815

MEDI-534 can be categorized as both a live-attenuated and vector vaccine.